[{"notes_id":"1_1686","category":"3","subcategory":"1","title":"Diabetes mellitus: GLP-1 drugs","body":"A number of drugs to treat diabetes mellitus have become available in recent years. Much research has focused around the role of glucagon-like peptide-1 (GLP-1), a hormone released by the small intestine in response to an oral glucose load<br \/><br \/>Whilst it is well known that insulin resistance and insufficient B-cell compensation occur other effects are also seen in type 2 diabetes mellitus (T2DM). In normal physiology an oral glucose load results in a greater release of insulin than if the same load is given intravenously - this known as the incretin effect. This effect is largely mediated by GLP-1 and is known to be decreased in T2DM.<br \/><br \/>Increasing GLP-1 levels, either by the administration of an analogue (glucagon-like peptide-1, GLP-1 mimetics, e.g. exenatide) or inhibiting its breakdown (dipeptidyl peptidase-4 ,DPP-4 inhibitors - the gliptins), is therefore the target of two recent classes of drug.<br \/><br \/><br \/><h5 class='notes-heading'>Glucagon-like peptide-1 (GLP-1) mimetics (e.g. exenatide)<\/h5><br \/>Exenatide is an example of a <span class=\"concept\" data-cid=\"389\">glucagon-like peptide-1 (GLP-1) mimetic<\/span>. These drugs increase insulin secretion and inhibit glucagon secretion. One of the major advances of GLP-1 mimetics is that they typically result in weight loss, in contrast to many medications such as insulin, sulfonylureas and thiazolidinediones. They are sometimes <span class=\"concept\" data-cid=\"9345\">used in combination with insulin in T2DM to minimise weight gain<\/span>.<br \/><br \/>Exenatide must be given by subcutaneous injection within 60 minutes before the morning and evening meals. It should not be given after a meal.<br \/><br \/>Liraglutide is the other GLP-1 mimetic currently available. One the main advantages of liraglutide over exenatide is that it only needs to be given once a day.<br \/><br \/>Both exenatide and liraglutide may be combined with metformin and a sulfonylurea. Standard release exenatide is also licensed to be used with basal insulin alone or with metformin. Please see the BNF for a more complete list of licensed indications.<br \/><br \/>NICE state the following:<br \/><br \/><div class='bs-callout bs-callout-default'><i><i><br \/>Consider adding exenatide to metformin and a sulfonylurea if:<br \/><ul><li>BMI >= 35 kg\/m\u00b2 in people of European descent and there are problems associated with high weight, or<\/li><li>BMI < 35 kg\/m\u00b2 and insulin is unacceptable because of occupational implications or weight loss would benefit other comorbidities.<\/li><\/ul><\/i><\/i><\/div><br \/>NICE like patients to have achieved a > 11 mmol\/mol (1%) reduction in HbA1c and 3% weight loss after 6 months to justify the ongoing prescription of GLP-1 mimetics.<br \/><br \/>The major adverse effect of GLP-1 mimetics is <span class=\"concept\" data-cid=\"388\">nausea and vomiting<\/span>. The Medicines and Healthcare products Regulatory Agency has issued specific warnings on the use of exenatide, reporting that is has been linked to <span class=\"concept\" data-cid=\"9346\">severe pancreatitis<\/span> in some patients.<br \/><br \/><br \/><h5 class='notes-heading'>Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g. Vildagliptin, sitagliptin)<\/h5><br \/>Key points<br \/><ul><li>dipeptidyl peptidase-4, DPP-4 inhibitors <span class=\"concept\" data-cid=\"11012\">increase levels of incretins (GLP-1 and GIP)<\/span> by <span class=\"concept\" data-cid=\"390\">decreasing their peripheral breakdown<\/span><\/li><li>oral preparation<\/li><li>trials to date show that the drugs are relatively well tolerated with no increased incidence of hypoglycaemia<\/li><li><span class=\"concept\" data-cid=\"3352\">do not cause weight gain<\/span><\/li><\/ul><br \/>NICE guidelines on DPP-4 inhibitors<br \/><ul><li>NICE suggest that a DPP-4 inhibitor might be preferable to a thiazolidinedione if further weight gain would cause significant problems, a thiazolidinedione is contraindicated or the person has had a poor response to a thiazolidinedione<\/li><\/ul>","notes_hash":"9675e795156932892b9b7522e1193b09","knowledge_graph_node_id_link":10924,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_829\" data-linkid=\"829\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_829\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">21<\/span><button type=\"button\" style=\"\" id=\"link_dislike_829\" data-linkid=\"829\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_829\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">16<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Recommendations\">2022 Type 2 diabetes guidelines<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/4Y7wdX7iEAY\" data-description=\"Type 2 diabetes agents and their mechanism of action\" data-upvotes=\"14\" data-downvotes=\"0\" data-media=\"694\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/4Y7wdX7iEAY\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/4Y7wdX7iEAY\" data-description=\"Type 2 diabetes agents and their mechanism of action\" data-upvotes=\"14\" data-downvotes=\"0\" data-media=\"694\">Type 2 diabetes agents and their mechanism of action<\/a><\/td><\/tr><tr><td><span ><small>Brandl's Basics - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1199\" data-mediaid=\"1199\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1199\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">14<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1199\" data-mediaid=\"1199\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1199\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/FePjKBoFICA\" data-description=\"How does sitagliptin work? DPP-4 inhibitors and GLP-1 mimetics\" data-upvotes=\"10\" data-downvotes=\"0\" data-media=\"759\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/FePjKBoFICA\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/FePjKBoFICA\" data-description=\"How does sitagliptin work? DPP-4 inhibitors and GLP-1 mimetics\" data-upvotes=\"10\" data-downvotes=\"0\" data-media=\"759\">How does sitagliptin work? DPP-4 inhibitors and GLP-1 mimetics<\/a><\/td><\/tr><tr><td><span ><small>Zero to Finals - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1326\" data-mediaid=\"1326\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1326\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">10<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1326\" data-mediaid=\"1326\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1326\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/APHeDOkJKQ0\" data-description=\" Pharmacology of drugs used to treat type 2 diabetes\" data-upvotes=\"7\" data-downvotes=\"2\" data-media=\"693\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/APHeDOkJKQ0\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/APHeDOkJKQ0\" data-description=\" Pharmacology of drugs used to treat type 2 diabetes\" data-upvotes=\"7\" data-downvotes=\"2\" data-media=\"693\"> Pharmacology of drugs used to treat type 2 diabetes<\/a><\/td><\/tr><tr><td><span ><small>Brandl's Basics - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1198\" data-mediaid=\"1198\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1198\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">7<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1198\" data-mediaid=\"1198\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1198\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">2<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/e7tBKFH341s\" data-description=\"Glucagon-like Peptide (GLP-1) and the treatment of diabetes\" data-upvotes=\"3\" data-downvotes=\"1\" data-media=\"688\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/e7tBKFH341s\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/e7tBKFH341s\" data-description=\"Glucagon-like Peptide (GLP-1) and the treatment of diabetes\" data-upvotes=\"3\" data-downvotes=\"1\" data-media=\"688\">Glucagon-like Peptide (GLP-1) and the treatment of diabetes<\/a><\/td><\/tr><tr><td><span ><small>Medicosis Perfectionalis - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1185\" data-mediaid=\"1185\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1185\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">3<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1185\" data-mediaid=\"1185\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1185\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"390":{"concept_text":"Gliptins (DPP-4 inhibitors) reduce the peripheral breakdown of incretins such as GLP-1","concept_percentile":"66"}},"category_name":"Endocrinology \/ Metabolic","subcategory_name":"Endocrinology","comment_count":8},"",[]]